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ABSTRACT 
To estimate the risk of sudden cardiac death (SCD) or sudden unexpected death (SUD) related 
to the individual antipsychotics, a meta-analysis of observational studies was performed. 
Adjusted Odds Ratio (OR) of SCD/SUD with 95% confidence intervals (CI) were extracted 
and pooled; heterogeneity was studied using Q statistic and I2 index, and its potential causes 
(e.g. hERG blockade potency) explored using meta-regression. Two cohort (740,306 person-
years) and four case-control (2,557 cases; 17,670 controls) studies, investigating nine 
antipsychotics, were included. Compared with non-users, the risk was increased for 
quetiapine (OR=1.72, 95%CI 1.33-2.23), olanzapine (OR=2.04, 1.52-2.74), risperidone 
(OR=3.04, 2.39-3.86), haloperidol (OR=2.97, 1.59-5.54), clozapine (OR=3.67, 1.94-6.94), 
and thioridazine (OR=4.58, 2.09-10.05). Heterogeneity was found (Q=20.0, p=0.01; 
I2=60.0%), and the increasing mean hERG blockade potency (p=0.01) accounted for 43% of 
this. The SCD/SUD risk differed between individual antipsychotics, and mean hERG 
blockade potency could be an explanatory factor. This should be considered when initiating 
antipsychotic treatment. 
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INTRODUCTION 
Some antipsychotic drugs have been shown to increase the risk of sudden cardiac death 
(SCD) and/or sudden unexpected death (SUD) (1, 2). One potential mechanism is via 
blockade of the cardiac potassium channel coded by hERG, the human Ether-à-go-go-Related 
Gene, usually referred to as the hERG channel (3), which is responsible for the rapid delayed 
rectifier potassium current (IKr). This blockade can result in delayed cardiac repolarization, 
prolongation of the QT interval on the ECG (4), and an increased risk of the polymorphic 
ventricular tachycardia termed torsade de pointe, a cardiac rhythm disorder that may result in 
cardiac arrest.  
Pharmacoepidemiological studies have previously been performed to investigate the risk of 
SCD/SUD associated with the use of antipsychotic drugs. Some of these compared typical 
and atypical antipsychotics and found no inter-class difference (1, 5, 6), but all had limited 
power to compare risks associated with the use of individual antipsychotics (1, 6). Thus, a 
meta-analysis of observational studies was conducted to evaluate the risk of SCD/SUD 
associated with the use of individual antipsychotic drugs and to explore sources of potential 
heterogeneity among drugs. 
 
RESULTS 
Study selection 
A systematic literature search identified 4,000 articles, 782 of which were duplicates and were 
thus removed. Of the 3,218 individual remaining articles, 3,178 were found to be irrelevant 
and excluded after review of title and abstract. The remaining 40 references underwent full-
text examination (see supplementary information file for selection process details), which 
generated the final selection of six observational studies eligible for the meta-analysis (see 
Figure S1 in the supplementary information file) (1, 2, 6-9). 
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Characteristics of included studies 
Of the selected six studies, two were cohort studies (1, 6) and four were case-control studies 
(2, 7-9). Four studies used medical record databases [four used primary care records (2, 6, 9), 
one used hospital records (8)], one used claims database records (1), and one was a field study 
(7). Four studies provided risk estimates for SCD (1, 6, 8, 9), and two for SUD (2, 7). Relative 
effect estimates were reported as odds ratio (OR), relative risk (or risk ratio, RR), or IRR 
(incidence rate ratio; Table 2).  
Concerning quality (10), the two cohort studies obtained the highest possible score on the 
Newcastle-Ottawa Scale (nine stars, see supplementary file, Table S1). For the case-control 
studies, this score ranged from seven to nine stars (see supplemental file, Table S2); 
weaknesses concerned the selection of controls from hospital rather than community settings 
(7, 8), and lack of information on response rate (8).  
Risk estimates were available for nine individual antipsychotics. Haloperidol was investigated 
in five studies; chlorpromazine, quetiapine, risperidone, and thioridazine were studied in three 
studies each; clozapine, flupentixol, fluphenazine, and olanzapine in one study each (Table 2). 
In the cohort studies, 435 cases of SCD/SUD were found in current users of antipsychotics 
(cumulated follow-up: 115,921 person-years), and 993 in the non-user group (648,414 person-
years); in case-control studies, 132 exposed cases (2,425 non-exposed cases) and 169 exposed 
controls (17,501 non-exposed controls) were found.  
 
Meta-analysis  
Risk estimates of SUD/SCD for individual drugs ranged from OR 0.06 (95%CI 0.00 to 6.00) 
for fluphenazine, to OR 9.40 (95%CI 0.21 to 420.75) for flupentixol, for which only one 
estimate was available from the selected studies (Figure 1). The risk was non-significantly 
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increased for chlorpromazine use compared to non-use (OR 1.66, 95%CI 0.83 to 3.29; three 
studies). It was found to be significantly increased for quetiapine (OR 1.72, 95%CI 1.33 to 
2.23; three studies) and olanzapine (OR 2.04, 95%CI 1.52 to 2.74; one study); higher 
estimates were observed for clozapine (OR 3.67, 95%CI 1.94 to 6.94; one study), haloperidol 
(OR 2.97; 95%CI 1.59 to 5.54; six studies), risperidone (OR 3.04, 95%CI 2.39 to 3.86; three 
studies), and thioridazine (OR 4.58, 95%CI 2.09 to 10.05; three studies).  
The incidence rate in the study reported by Ray et al. was 1.4 per 1,000 person-years (95%CI 
1.3 to 1.5) in the non-use group (1); the attributable number of cases was then calculated for 
the studied antipsychotics, and it varied from 1.0 per 1,000 person-years (95%CI 1.3 to 1.5) 
for quetiapine, to 5.1 per 1,000 person-years (95%CI 1.5 to 13.8) for thioridazine (Table 3). 
A significant heterogeneity between the individual risk estimates (intra-drug heterogeneity) 
was found only for haloperidol (Q = 16.7, p = 0.002; I2 = 76%, Figure 1). Conversely, a 
significant heterogeneity between the pooled estimates of each drug (inter-drug heterogeneity) 
was found (Q = 20.0, p = 0.01; I2 = 60%; Figure 1).  
 
Meta-regression  
The overall OR of SUD/SCD for antipsychotics was 2.65 (95%CI 2.13 to 3.29). Univariate 
meta-regression analyses (11, 12) found that heterogeneity was explained by mean hERG 
blockade potency (p = 0.01; Figure 2), but not by individual study (p = 0.61), study design 
(cohort versus case-control; p = 0.21), mean age (p = 0.32), proportion of males (p = 0.41), or 
antipsychotic type (typical versus atypical; p = 0.44). The multivariate meta-regression model 
(13), built using manual backward elimination, found that heterogeneity was explained only 
by mean hERG blockade potency (i.e. this was the only variable that remained).  
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The R2 index, used to quantify the proportion of the variability in the risk with each potential 
source of heterogeneity (14, 15), for mean hERG blockade potency was 43%, while for other 
covariates was nil or very low (2% for study design). 
 
DISCUSSION 
The present meta-analysis included data for nine antipsychotics, the use of six of which being 
associated with an increased risk of SCD/SUD. Heterogeneity was found between drugs; the 
highest risk was associated with clozapine, haloperidol, risperidone, and thioridazine, and the 
data indicate that there were a considerable number of attributable fatal cases related to these 
drugs. Meta-regression indicated that the risk of SCD/SUD increased with increasing of mean 
hERG blockade potency.  
hERG channel blockade is recognized as one of the mechanisms for QT prolongation which is 
an intermediate finding for torsade de pointe and ventricular arrhythmia (3). Although this 
association is evident, up to today the hERG affinity has not been related to SCD/SUD risk in 
clinical practice. The present study support the hypothesis that hERG affinity of 
antipsychotics is an independent risk factor for SCD/SUD. In the present analysis, R2 index 
indicates that hERG blockade potency explains more than 40% of the heterogeneity found 
among drug estimates. However, the performance of the R2 index in meta-regressions are 
limited when less than 40 estimates are included in the analysis (15). Moreover, published 
data concerning hERG blockade potency of antipsychotics is limited, and other mechanisms 
may also be involved (e.g. drug effects on other myocardial ion channels). Despite these 
considerations, it is of note that among the variables we tested as potential cause of 
heterogeneity, mean hERG blockade potency was the only one that was significantly 
associated both in univariate and multivariate analyses; forcing all variables in the model, did 
not alter this result (data not shown).  
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The high risk of cardiac arrhythmias associated with thioridazine use is widely accepted, 
resulting in the drug being withdrawn in 2005 in several countries; this study confirmed its 
strong association with SCD/SUD. The increased risk found of SCD/SUD for clozapine 
should be considered with caution: the risk estimate was not precise (only one study for this 
drug), and the reported hERG blockade potency is highly variable between assays (IC50 from 
0.32 to 2.63 mmol) (16-18). More importantly, as a second-line treatment for resistant 
psychoses often used at high-dose (1, 19), which could lead to concentrations that far exceed 
its hERG IC50. Additionally, clozapine is the only antipsychotic related to myocarditis and 
cardiomyopathy (20) which, if unrecognized in fatal cases, could be classified as a sudden 
death.  
The risk associated with haloperidol was also high. This is consistent with its extremely high 
potency for hERG channel blockade, and its myocardial cell concentration being higher than 
other antipsychotics (21). Nevertheless, the interpretation of this result requires caution owing 
to the heterogeneity found between its estimates, with consequently wide 95%CIs. This could 
be related to multiple indications of haloperidol (including delirium or non-psychiatric 
conditions), and different routes of administration. Further investigations are required to 
clarify this issue and to make more definitive conclusions about its risk.  
For risperidone, the magnitude of risk was consistent between individual study estimates. 
Risperidone has one of the highest mean hERG channel blockade potency, and a high intra-
myocardial concentration (21). A potential alternative explanation is that risperidone is 
preferentially prescribed to at-risk patients, such as the elderly with dementia for which is it 
indicated. However, there was a lack of data regarding the population using risperidone that 
limited investigation of such aspects, as was the case for other drugs considered herein. 
Quetiapine, a drug with low mean hERG blockade potency, showed a lower increase in the 
risk of SCD/SUD, and estimates among the three included studies were consistent. This study 
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indicates that quetiapine is the atypical antipsychotic related to the lower increased risk of 
SCD/SUD.  
Olanzapine, which also has low mean hERG channel blockade potency, was also associated 
with more limited increase in risk; although only one study was retrieved, this was large. 
Other epidemiological evidence indicate that olanzapine has a lower risk of SCD when 
compared with haloperidol, but that this risk is higher than that for quetiapine (22). For 
chlorpromazine and flupentixol the increase in risk was not significant; there was no evidence 
of heterogeneity among estimates for chlorpromazine, and for flupentixol only one study was 
included, and not many patients were exposed, limiting the conclusions that can be drawn. 
According to our hypothesis concerning hERG channel blockade, the high potency of 
flupentixol does however suggest the need for further investigations. Fluphenazine was 
associated with a point estimate less than 1.0 yet, as for flupentixol, the estimate was derived 
from a single case-control study and the 95%CI are too wide to allow any meaningful 
conclusion. 
This meta-analysis has certain limitations. For instance, studies evaluating SCD with those 
evaluating SUD, which could also be related to other diagnoses, such as tonic-clonic epilepsy, 
were pooled. Nevertheless, the included studies that did investigate SUD, alone or in relation 
with SCD, used strict criteria to avoid the inclusion of unexpected death from causes other 
than arrhythmias (2, 7, 23). Despite this wide definition, the present analysis was only able to 
pool data for nine of the more than fifty antipsychotics available worldwide, but these do 
represent the most commonly used typical and atypical antipsychotics. Also, the analysis 
according to dose was performed in only two of the included studies (1, 7), and no 
information was found concerning different formulations of included drugs (e.g. prolonged 
release) or different routes of administration. This advocates for the conduct of additional 
  9 
 
observational studies focusing on the risk of SCD/SUD associated with the use of individual 
antipsychotics, such as those envisioned in the ARITMO project. 
Another important aspect is that patients with psychiatric bipolar disorders, schizophrenia, 
and dementia have an increased risk of all-cause mortality in comparison with the general 
population, thus an indication bias cannot be excluded. It is likely that this would not be 
differential across the drugs used as first-line treatments, while it is likely to have been greater 
for clozapine, a second-line treatment reserved for more severe psychoses, and for atypical 
antipsychotics, which are more commonly used in the elderly. Studies did address this issue 
by matching or adjusting for psychiatric disorders, cardiovascular diseases, or through 
propensity scores; in addition one study also adjusted for hypokalemia and alcohol abuse (2), 
and a second for use of drugs that could induce hypokalemia (9). The results provided by the 
latter studies did not differ to those provided by others. Residual confounding could also be 
present in all included studies that, even matched or adjusted, remain observational and thus 
cannot control for all potential risk factors of SCD/SUD. One of these potential residual 
confounders is obesity, which was considered in none of the included studies. Obesity was 
recently related to SCD in patients in middle-aged, non-smoking individuals (24); 
nevertheless, this increased risk seems mediated by traditional cardiovascular risk factors 
(such as arteriosclerosis), which were taken into account in all of the included studies.  
The results may also be affected by the quality of the included studies. According to the 
Newcastle-Ottawa scale, the quality of five studies reached the highest value; for others it was 
one to two points below this. The quality of the studies reported by Kenbubpha et al. (7) and 
by Reilly et al. (8) was adversely affected by the selection of controls in hospital as opposed 
to community settings, but, as in these case-control studies cases were selected from the same 
population, this may not be too great a concern. The study reported by Reilly et al. (8) was 
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also affected by non-response rate as for certain variables there was missing data, but it was 
not made clear in the published article whether there was any imbalance across groups.  
Heterogeneity is also a concern in meta-analyses, yet it is common when meta-analyses of 
observational studies are performed (25), and it may reach very high values (26, 27). When 
heterogeneity is found intra-drug this could be considered a limitation, but when this is inter-
drug, this could be considered as an interesting aspect to investigate the risk profiles of drugs 
in a real-life setting. In this study we investigated heterogeneity using meta-regression, which 
could also be affected by certain limitations, such as aggregation or ecological bias (28, 29). 
However, among tested variables, aggregation bias could affect only age and gender, while 
the multilevel meta-regression performed excluded ecological bias. The estimations for each 
antipsychotic are affected by a certain degree of imprecision. This affects in particular drugs 
rarely used in clinical practice, such as flupentixol or fluphenazine. From a general point of 
view, imprecision leads to an underestimation of heterogeneity among estimates; thus in the 
present article, it could have reduced the chance to find a difference in risk among studied 
drugs. 
More generally, a publication bias could have affected results. Nevertheless, in observational 
studies this is difficult to detect and to evaluate as registers are not systematically used as they 
are for clinical trials. In addition, owing to the differential risk among the investigated drugs, 
a funnel plot could be appropriate and informative when at least ten estimates for the same 
drug is available (30), which was not the case in the present meta-analysis. The existence of a 
publication bias could be considered unlikely for different reasons: the first studies were 
published in 2002 (7, 8); only two of the six studies were privately funded (2, 6); the included 
articles studied antipsychotics as a class, without any specific analysis for a single drug; this 
meta-analysis evaluated more than 700,000 person-year for cohort studies, and more than 
3,000 cases for case control ones; the results are coherent with pharmacological profile of the 
  11 
 
studied drugs. If a selective publication for positive results could be expected for 
observational studies, the large effect size found in this meta-analysis strongly reduce the 
possibility that new evidences changes substantially the results of the present meta-analysis.  
In conclusion, this study strongly suggests that the risk of SCD/SUD differs between 
individual antipsychotics, and that this difference in absolute terms is clinically important. It 
also suggests that mean hERG blockade potency is an explanatory factor for this difference in 
real-life situations. This should be considered when initiating antipsychotic treatment, in 
particular as indications for these have been widened to non-schizophrenic patients in whom 
arrhythmogenic risk is less extensively studied. 
 
METHODS 
Data sources and data extraction 
As part of the ARITMO project, an extensive systematic review was conducted to identify 
observational studies that evaluated the risk of ECG disorders and ventricular arrhythmias 
related to antipsychotics, anti-infectives, and antihistamines. The results concerning use of 
individual antipsychotics and risk of SCD/SUD in comparison with non-use are presented 
herein. The studies evaluating SCD, defined as sudden natural death attributable to cardiac 
causes or non-attributable to a non-cardiac cause, and SUD, defined as sudden death both of 
cardiac origin or other natural origin, were considered eligible to be included in the present 
meta-analysis. 
Studies eligible for inclusion in this meta-analysis were cohort studies (prospective or 
retrospective), case-control studies, or case-based studies including case-crossover and self-
controlled case series, providing adjusted risk estimates of SCD/SUD. For this study, a 
protocol specifying the meta-analysis objective and context, the principles and modalities of 
the literature search, and the data analysis was developed during the ARITMO project period. 
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This study followed Preferred Reporting Items for Systematic Reviews and Meta-analyses 
(PRISMA) statement, and Meta-analysis of Observational Studies in Epidemiology (MOOSE) 
reporting guidelines (see supplement file) (31, 32).  
References meeting the inclusion criteria were searched in Medline, EMBASE, and ISI web 
of Knowledge. The search strategy with detailed literature keywords used in Medline 
database is reported in the data supplement. EndNote X4 for Macintosh (Thomson Reuters) 
was used to compile the bibliography. This search was last updated on February 13, 2014. 
The process used for the identification and selection of the retrieved studies is detailed in the 
data supplement.  
Data were extracted from the selected studies using a standardized form. These included the 
definition of the events of interest, the number of cases in the exposed and non-exposed group 
for cohort studies, the number of exposed cases and exposed controls for case-control studies, 
and the adjusted risk measure of SCD/SUD for each individual antipsychotic.  
The Newcastle-Ottawa Scale was used for assessing the quality of the included studies. Each 
study was scored from zero to nine stars for the selection and the comparability of the groups, 
and for the ascertainment of either the exposure for case-control or outcome of interest for 
cohort studies (10).  
 
Meta-analysis 
The overall risk of SCD/SUD associated with the use of each individual antipsychotic was 
estimated. Adjusted estimates of risk were extracted from each selected study, and included in 
a forest plot as OR, which is a good risk measure when the diseases are rare, and when 
different study designs are pooled in a single meta-analysis. For each antipsychotic, the 
pooled OR with 95% confidence interval (CI) for use versus non-use was computed using 
inverse variance method and random-effect models (11). Statistical heterogeneity was 
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evaluated using the Q statistic (with p<0.10 considered significant) and the I2 index (33) 
between the individual risk estimates for a given drug (intra-drug heterogeneity), and between 
the pooled estimates of each drug (inter-drug heterogeneity). The meta-analysis was 
conducted using Review Manager software (RevMan version 5.2, The Nordic Cochrane 
Centre, The Cochrane Collaboration); all p values were two sided. 
The cohort study reporting the lowest incidence rate of SCD/SUD in the non-user group was 
used to calculate the number of attributable cases (and the corresponding 95% CI) per 1000 
person-years. This incidence rate in this non-user group was multiplied by the pooled OR 
minus 1.0 for each antipsychotic associated with an increased risk of SCD/SUD.  
 
Meta-regression analysis 
Random-effect meta-regression analyses were performed to explore sources of heterogeneity 
between the individual estimates of SCD/SUD risk (11, 12). Potential sources of 
heterogeneity considered included: individual study (each included study was considered as a 
unique value of this variable), study design (cohort versus case-control), antipsychotic type 
(typical versus atypical), mean age (continuous variable), gender (proportion of males, 
continuous variable), and blockade potency of hERG channels (continuous variable). For the 
latter, for each studied drug, the mean published values for the concentrations inhibiting 50% 
of hERG channels (IC50) in transfected mammalian cells was used (Table 1) (16-18, 34-46). 
The ARITMO consortium researchers retrieved the references used for this calculation via a 
systematic review of preclinical data of hERG channel blockade potency (47). Each potential 
source of heterogeneity was investigated using univariate meta-regression models. A 
multivariate meta-regression model was then built using manual backward elimination 
including only sources associated with p<0.05 (13). The R2 index was used to quantify the 
proportion of the variability in the SCD/SUD risk associated with each potential source of 
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heterogeneity (14, 15). The R2 index informs on the practical significance, or the degree of 
influence, of a variable in the heterogeneity of the effect sizes in a meta-analysis (e.g. if a 
variable with R2 = 20%, then this variable explains 20% of the heterogeneity). The meta-
regression analyses were performed using R software (version 3.0.3) via the “metafor” 
package (48). 
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STUDY HIGHLIGHTS 
What is the current knowledge on the topic? 
Taken alone, all published observational studied have limited power to compare risks of 
SCD/SUD associated with the use of individual antipsychotics. 
 
What question did this study address? 
Is there a difference in risk of SCD/SUD among individual antipsychotics? 
 
What this study adds to our knowledge?  
This study found that the risk of SCD/SUD varies among individual antipsychotics. This 
variation is not related to a class effect (typical vs. atypical antipsychotics), but it seems 
related to potency of antipsychotics to block hERG channels, which is particularly high for 
risperidone, haloperidol and thioridazine.  
 
How this might change clinical pharmacology and therapeutics? 
Indications of antipsychotics have been recently widened to non-schizophrenic patients. The 
number of exposed patients and the number of attributable cases of SCD/SUD is thus 
increasing. In order to prevent as possible their occurrence, the findings of the present studies 
should thus be considered when risks and benefits are balanced before the antipsychotic 
treatment initiation. 
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FIGURES LEGENDS 
 
Figure 1. Forest plot of the risk of SCD/SUD related to individual antipsychotics. Odds ratio 
for individual antipsychotics obtained from included studies is presented with 95% 
confidence interval (CI); arrowheads indicate the CI exceeding the limits of the graph. Overall 
odds ratio (OR) for individual drugs is also presented (black diamonds). Weight of each 
estimate in the pooled OR for each drug was calculated using the inverse variance method. 
 
 
Figure 2. Log Odds Ratio of Sudden Cardiac Death/Sudden Unexpected death according to 
the 50% inhibitory concentration (IC50) of hERG channel for individual antipsychotics. Each 
estimate of risk is represented by a circle, the area of which is proportional to the estimation 
weight in the meta-analysis (larger studies correspond to larger circles). The black line 
represents the predictive values obtained by the random-effects meta-regression model (p = 
0.01). 
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TABLES (SEPARATE FILES AFTER BIBLIO) 
 
Table 1. Fifty percent of inhibitory concentration (IC50) of hERG channel, expressed as 
mmol, of antipsychotics included in this meta-analysis. 
 IC50  
 mean (SD) min max 
Typical Antipsychotics    
 Chlorpromazine (39)  1.56* -- -- 
 Flupentixol (45) 0.59* -- -- 
 Fluphenazine (45) 1.00* -- -- 
 Haloperidol (16, 37, 38, 40, 42, 46) 0.05 (0.05) 0.02 0.17 
 Thioridazine (16, 36-41, 43, 45) 0.18 (0.11) 0.03 0.39 
     
Atypical antipsychotics    
 Clozapine (16-18)  1.82 (1.30) 0.32 2.63 
 Olanzapine (16, 36, 41, 44)  3.01 (2.47) 0.23 6.01 
 Quetiapine (41)  5.77* -- -- 
 Risperidone (16, 34, 35, 41) 0.15 (0.10) 0.01 0.26 
* Only one estimate; SD: Standard deviation. 
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Table 2. Characteristics of selected studies. 
 Data source and 
setting 
Study 
 population 
Comparison group, adjustment or matching 
variables of interest 
Outcome and definition Sample size Drugs NOS Score  
(Up to 9) 
Risk 
measure 
Cohort Studies     P-Ys (n cases) Studied drugs (n cases; n P-
Ys) 
  
 Jones, et al.(6) Primary care 
records database 
Mean age (y): 60  
Male (%): 42 
Patients with psychiatric diagnoses, but 
non-users of antipsychotics. Adjusted for 
age, sex, psychiatric history, CV history, 
CV risk factors, drug use 
SCD*  28,516 (191) TA: haloperidol (47; 1,236); 
AA: quetiapine (46; 3,407) 
9 RR 
 Ray, et al.(1) Claims database, 
outpatients 
Mean age (y): 46 
Male (%): 35 
Non-users of antipsychotics matched for 
age, sex and first day of follow-up. 
Adjusted for psychiatric comorbidities, CV 
risk, drug dose 
SCD: sudden pulseless 
condition that was fatal, and 
consistent with a ventricular 
tachyarrhythmia 
735,889 (1,237) TA: haloperidol (58; 21,728), 
thioridazine (65; 15,715);  
AA: clozapine (19; 4,654), 
olanzapine (75; 27,257), 
quetiapine (40; 17,355), 
risperidone (85; 24,589),  
9 IRR 
          
Case-control studies     Cases / controls Studied drugs (n exposed 
cases; n exposed controls) 
  
 Jolly, et al.(2) Primary care 
records database 
Mean age (y): 68  
Male (%): 67 
Controls matched for age, sex, existence of 
CV history. Adjusted for CV disease, 
epilepsy, renal dysfunction, alcohol abuse, 
hypokaliemia 
SUD: post-mortem examination 
where a clear cause of death 
could not be identified 
1,010 / 3,030 TA: chlorpromazine (4; 8), 
haloperidol (6; 3); 
AA: quietiapine (3; 4), 
risperidone (15; 10) 
9 OR 
 Kenbubpha, et 
al.(7) 
Hospital based 
field study 
Mean age (y): 41 
Male (%): 63 
Patients with CV history were excluded. 
Controls matched on sex. Adjusted for age, 
use of other antipsychotics, number of 
psychiatric admissions  
SUD:  a person observed to be 
alive and experiences onset of 
symptoms and is dead within 
one hour. 
54 / 108 TA: chlorpromazine (23; 54), 
thioridazine (21; 18) 
8 OR 
 Reilly, et al.(8) Hospital records Mean age (y): 67 
Male (%): 31 
Controls matched for age, sex, in-patient 
stay duration. Adjusted for psychiatric 
disorder, CV diseases, COPD, mood 
stabilizer drugs  
SCD: sudden death without 
evidence of non-cardiac cause 
69 / 69 TA: chlorpromazine (5; 6), 
flupentixol (5; 3), 
fluphenazine (3; 6), 
haloperidol (7; 13), 
thioridazine (24; 19) 
7 OR 
 Van Noord, et al.(9) Primary care 
records database 
Mean age (y): 73 
Male (%): 58 
Controls matched for age, sex, calendar 
time. Adjusted for CV diseases, CV drugs, 
diabetes, hypercholesterolemia, use of QTc 
prolonging drugs, CYP3A4 affecting drugs, 
laxatives, diuretics, oral corticosteroids, 
beta-agonists 
SCD: sudden and witnessed 
natural death attributable to 
cardiac causes, or unwitnessed, 
unexpected death of someone 
seen in a stable medical 
condition less than 24 h 
previously with no evidence of 
a non-cardiac cause 
1,424 / 14,443 TA: haloperidol (11; 16);  
AA: risperidone (5; 9) 
9 OR 
*Derived from death certificates with International Classification of Diseases 10th version using the following codes: I10, I11.9, I20, I21, I22, I23, I24, I25, I42.8, I42.9, I46, I47, I49.0, I49.8, 
I49.9, I51.6, I51.9, I70.9, R09.2, R96.1, R98, from Read codes in GPRD that correspond to these ICD10 codes, or from free text in the ± 3 weeks before or after the death recording.  
AA: Atypical antipsychotics; COPD: Chronic Obstructive Pulmonary Disease; CV, Cardiovascular; CYP3A4: cytochrome p450 isoform 3A4; IRR, Incidence Rate Ratio; OR, Odds Ratio, RR, 
relative ratio; P-Ys, Person-years; QTc: corrected QT tract of electrocardiogram; SCD, Sudden cardiac death; SUD, Sudden unexpected death; TA: typical antipsychotics. . 
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Table 3. Number of attributable cases per 1000 person-years 
 
Attributable cases per 1000 P-Y (95% CI) 
Quetiapine 1.0 (0.4-1.9) 
Olanzapine 1.5 (0.7-2.7) 
Haloperidol 2.8 (0.8-6.9) 
Risperidone 2.9 (1.9-4.4) 
Clozapine 3.8 (1.3-9.1) 
Thioridazine 5.1 (1.5-13.8) 
 
 
 
 
